Workflow
药用辅料
icon
Search documents
突发!一A股董事长逝世
Zhong Guo Ji Jin Bao· 2025-08-27 02:07
Core Viewpoint - The passing of Yin Zhenglong, the controlling shareholder and chairman of Shanhe Pharmaceutical Auxiliary, marks a significant loss for the company and the industry, as he dedicated his life to the development of China's pharmaceutical sector and the company's growth [1][3]. Company Overview - Shanhe Pharmaceutical Auxiliary focuses on the research, production, and sales of pharmaceutical excipients, including fillers, adhesives, disintegrants, lubricants, and coating materials for oral solid dosage forms [4]. - As of August 26, the company's stock price was 14.34 yuan per share, with a total market capitalization of 3.4 billion yuan [4]. - The number of shareholders as of June 30, 2025, was 17,500 [4]. Leadership Transition - Following Yin Zhenglong's death, the company confirmed that the board of directors would remain operational, and the management team would continue its duties without disruption [4]. - The position of chairman is currently vacant, and the company will expedite the election of a new chairman in accordance with relevant laws and regulations [4]. - Until a new chairman is elected, the current director and general manager, Song Daocai, will temporarily assume the responsibilities of chairman and legal representative [4]. Contributions and Legacy - Yin Zhenglong was instrumental in transforming Shanhe Pharmaceutical Auxiliary from a local pharmaceutical factory into a publicly listed company on the Shenzhen Stock Exchange, contributing significantly to the domestic pharmaceutical excipient industry [3]. - His leadership and dedication earned him deep respect and affection from employees, and the company expressed heartfelt condolences to his family [3].
突发!一A股董事长逝世
中国基金报· 2025-08-27 01:58
Core Viewpoint - The passing of Yin Zhenglong, the controlling shareholder and chairman of Shanhe Pharmaceutical Auxiliary, marks a significant loss for the company and the industry, as he dedicated his life to the development of China's pharmaceutical sector and the advancement of domestic pharmaceutical excipients [1][3]. Company Overview - Shanhe Pharmaceutical Auxiliary focuses on the research, production, and sales of pharmaceutical excipients, including fillers, adhesives, disintegrants, lubricants, and coating materials for oral solid dosage forms [5]. - As of August 26, 2025, the company's stock price was 14.34 yuan per share, with a total market capitalization of 3.4 billion yuan [5]. - The number of shareholders as of June 30, 2025, was 17,500 [5]. Leadership Transition - Following Yin Zhenglong's death, the company confirmed that the board of directors would remain operational and that the management team would continue to perform their duties without disruption [4]. - The company will conduct a board member election and appoint a new chairman in accordance with relevant laws and regulations. In the interim, Song Daocai, a current board member and general manager, will assume the responsibilities of chairman and legal representative [5].
山河药辅: 关于公司控股股东、实际控制人、董事长逝世的公告
Zheng Quan Zhi Xing· 2025-08-27 00:18
证券代码:300452 证券简称:山河药辅 公告编号:2025-049 债券代码:123199 债券简称:山河转债 安徽山河药用辅料股份有限公司 作为公司的创始人,尹正龙先生自公司成立以来,一直担任公司 董事长、总经理等职务,经过 20 多年对行业的坚守,带领公司将地 方制药厂一个小的辅料车间走向资本市场,成功在深圳证券交易所上 市,他把一生奉献给了企业,为公司创立、成长和发展做出了巨大的 贡献。他开拓进取,呕心沥血,为公司的发展奠定了长期、稳定、健 康发展的基础;他才华卓越,谦虚待人,关爱员工,深受公司全体员 工的爱戴。我们为失去这样一位好领导、好兄长、好榜样无比悲痛! 公司全体董事、高级管理人员和全体员工,对尹正龙先生为公 司付出的无数心血和做出的巨大贡献表示最衷心感谢,对尹正龙先生 的逝世致以沉痛哀悼和怀念,并向尹正龙先生的家人致以深切慰问。 尹正龙先生持有公司股份 63,057,454 股,占公司股份总额的 份将按相关法律法规办理相关手续,公司将根据后续事项进展情况及 时履行信息披露义务。 尹正龙先生的逝世不会导致公司董事会成员人数低于法定人数, 不会影响公司董事会的正常运作。公司经营管理团队正常履职 ...
山河药辅: 董事会决议公告
Zheng Quan Zhi Xing· 2025-08-26 16:13
证券代码:300452 证券简称:山河药辅 公告编号:2025-047 债券代码:123199 债券简称:山河转债 安徽山河药用辅料股份有限公司 第七次会议于 2025 年 8 月 26 日上午在公司三楼会议室召开,应出席会议 董事 8 人,实际出席会议董事 8 人。公司第六届董事会第七次会议通知已 于2025 年 8 月 17 日以电子邮件、 传真及电话通知的方式向全体董事送达, 会议由董事长尹正龙先生主持。会议的召开符合《中华人民共和国公司法》 和《公司章程》的有关规定。本次会议经审议逐项表决作出如下决议: 一、审议通过《关于 2025 年半年度报告全文及其摘要的议案》 公司董事会成员认真审核了公司 2025 年半年度报告全文及其摘要, 认为该报告所载资料真实、准确、完整地反映了本公司的实际情况,不存 在虚假记载、误导性陈述或者重大遗漏。 表决结果:同意 8 票,反对 0 票,弃权 0 票。 本议案在提交董事会审议前已经公司董事会审计委员会审议通过,并 同意将该议案提交公司董事会审议。 第六届董事会第七次会议决议公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏。 安徽 ...
山河药辅: 安徽山河药用辅料股份有限公司向不特定对象发行可转换公司债券第一次临时受托管理事务报告(2025年度)
Zheng Quan Zhi Xing· 2025-08-06 04:09
证券代码:300452 证券简称:山河药辅 债券代码:123199 债券简称:山河转债 安徽山河药用辅料股份有限公司 向不特定对象发行可转换公司债券 第一次临时受托管理事务报告 (安徽省合肥市梅山路 18 号) 二〇二五年八月 重要声明 本报告依据《公司债券发行与交易管理办法》 (以下简称《行为准则》)、 《安徽山河药用辅料 股份有限公司向不特定对象发行可转换公司债券之受托管理协议》 (以下简称《受 托管理协议》)、《安徽山河药用辅料股份有限公司向不特定对象发行可转换公司 债券并在创业板上市募集说明书》 (以下简称《募集说明书》)等相关规定、公开 信息披露文件、安徽山河药用辅料股份有限公司(以下简称山山河药辅、、 (以下简称《管理办法》)、 《公 司债券受托管理人执业行为准则》 山发行 人、或山公司、)提供的相关资料等,由本期债券受托管理人国元证券股份有限 公司(以下简称山国元证券、)编制。国元证券对本报告中所包含的从上述文件 中引述内容和信息未进行独立验证,也不就该等引述内容和信息的真实性、准确 性和完整性做出任何保证或承担任何责任。 本报告不构成对投资者进行或不进行某项行为的推荐意见,投资者应对相关 事宜 ...
山河药辅:新增1种药用辅料产品甘露醇丸芯
Cai Jing Wang· 2025-08-04 10:04
8月4日,山河药辅发布关于公司新增产品品种的公告。披露近日公司新增 1 种药用辅料产品:甘露醇丸 芯获得国家药品监督管理局药品审评中心的登记号,为 F20250000241。截止公告日,山河药辅已有 47 种产品获得 CDE 登记号。 3.改善口感:甘露醇本身具有清凉的甜味,溶解时吸热产生清凉感; 4.制备复方制剂:不同药物可分别载到不同的甘露醇丸芯批次上,可以避免不同药物成分之间的物理化 学不相容,实现不同药物不同的释放速度; 5.可直接作为渗透性利尿药使用。 公司新增产品品种,扩大了公司产品生产范围,将对公司后续年度的经营产生一定的积极影响。 (企业公告) 甘露醇丸芯是由 D-甘露糖醇及其他辅料制成的白色或类白色球形小丸,主要用作肠溶微丸制剂和缓控 释微丸制剂的载体,也可直接作为药物微丸。具有以下特点: 1.作为药物层积的载体:甘露醇丸芯表面光滑、规则,粒径分布均一,为药物层积提供了理想的起始平 台,确保药物层均匀、牢固; 2.制备缓控释微丸:甘露醇丸芯作为惰性核心,不影响药物的释放行为,使得释放特性主要由包衣膜控 制; ...
山河药辅新增1种药用辅料产品
Zhi Tong Cai Jing· 2025-08-04 08:42
山河药辅(300452)(300452.SZ)公告,公司新增1种药用辅料产品:甘露醇丸芯获得国家药品监督管理 局药品审评中心(简称"CDE")的登记号,为F20250000241。甘露醇丸芯是由D-甘露糖醇及其他辅料制成 的白色或类白色球形小丸,主要用作肠溶微丸制剂和缓控释微丸制剂的载体,也可直接作为药物微丸。 ...
山河药辅(300452.SZ):新增1种药用辅料产品
Ge Long Hui A P P· 2025-08-04 08:40
甘露醇丸芯是由D-甘露糖醇及其他辅料制成的白色或类白色球形小丸,主要用作肠溶微丸制剂和缓控 释微丸制剂的载体,也可直接作为药物微丸。 格隆汇8月4日丨山河药辅(300452.SZ)公布,近日安徽山河药用辅料股份有限公司新增1种药用辅料产 品:甘露醇丸芯获得国家药品监督管理局药品审评中心(简称"CDE")的登记号,为F20250000241。截止 公告日,山河药辅已有47种产品获得CDE登记号,详情登陆CDE官网查询。 ...
山河药辅(300452.SZ)新增1种药用辅料产品
智通财经网· 2025-08-04 08:39
智通财经APP讯,山河药辅(300452.SZ)公告,公司新增1种药用辅料产品:甘露醇丸芯获得国家药品监 督管理局药品审评中心(简称"CDE")的登记号,为F20250000241。甘露醇丸芯是由D-甘露糖醇及其他辅 料制成的白色或类白色球形小丸,主要用作肠溶微丸制剂和缓控释微丸制剂的载体,也可直接作为药物 微丸。 ...
山河药辅: 可转换公司债券付息公告
Zheng Quan Zhi Xing· 2025-06-04 11:33
Group 1 - The company, Anhui Shanhe Pharmaceutical Auxiliary Materials Co., Ltd., is issuing convertible bonds named "Shanhe Convertible Bonds" with a face value of 1,000.00 yuan and an annual interest of 5.00 yuan (including tax) [1][2] - The interest payment method for the convertible bonds is annual, with the first interest payment starting from the issuance date [1][2] - The interest calculation formula is provided, where the annual interest (I) is calculated as I = B × i, with B being the total face value held and i being the annual coupon rate [1] Group 2 - The interest payment date is set for each year on the anniversary of the bond issuance, with provisions for adjustments if the date falls on a holiday [2] - The bondholders must be registered with the China Securities Depository and Clearing Corporation Limited by the specified date to receive interest payments [4] - The company has appointed the China Securities Depository and Clearing Corporation Limited to handle the interest payments [4] Group 3 - Tax obligations for interest income are specified, with a 20% withholding tax for individual bondholders, while qualified foreign institutional investors (QFII and RQFII) are exempt from corporate income tax and value-added tax [3][5] - The company does not withhold taxes for other bondholders, who are responsible for their own tax payments [3][5] - The announcement includes contact information for inquiries regarding the bond issuance [5]